Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy and Liver-Directed Therapy for Downstaging HCC
NCT07489976Phase 2Recruiting
- Sponsor
- Judongyang
- Start
- Apr 2026
- Primary completion
- Apr 2030
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab and durvalumab in hepatocellular carcinoma (HCC), sponsored by Judongyang. Primary endpoint: Proportion of participants downstaged from beyond UCSF criteria to within Milan criteria by radiographic assessment at 12 months. Started Apr 2026; status: recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07489976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489976.